News & Events about Sensei Biotherapeutics Inc.
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo(...
Citigroup started coverage on shares of Sensei Biotherapeutics (NASDAQ:SNSE Get Rating) in a research report sent to investors on Tuesday , The Fly reports. The brokerage issued a buy rating on the stock. Separately, Oppenheimer upgraded shares of Sensei Biotherapeutics from a market perform...
Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) (Sensei or the Company). The investigations concern whether certain of the Senseis officers and directors breached their fiduciary duties to...
- Closes Boston research site, reducing workforce by approximately 40 percent to decrease operating expenses - - Continued focus on development of TMAb programs; IND submission for lead antibody SNS-101 anticipated in or prior to April 2023 - - Cash runway extended into the second half of 2025 - ...
Globe Newswire
2 months ago
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in...